[Translation] A multicenter, randomized, open, parallel controlled comparison of the efficacy and safety of semaglutide injection (CA505) and Novotel® in the treatment of type 2 diabetes

主要目的：以原研药物司美格鲁肽注射液（诺和泰®）为对照，评价重庆宸安生物制药有限公司研制的司美格鲁肽注射液（CA505）治疗成人2型糖尿病的疗效。次要目的：1）以原研药物司美格鲁肽注射液（诺和泰®）为对照，评价重庆宸安生物制药有限公司研制的司美格鲁肽注射液（CA505）治疗成人2型糖尿病的安全性。2）比较司美格鲁肽注射液（CA505）和诺和泰®在2型糖尿病患者中多次给药后关键药代动力学（PK）参数（AUC0-τ、Css,min）的相似性。

[Translation]

Primary objective: To evaluate the efficacy of semaglutide injection (CA505) developed by Chongqing Chen'an Biopharmaceutical Co., Ltd. in the treatment of type 2 diabetes in adults, using the original drug semaglutide injection (Novota®) as a control. Secondary objectives: 1) To evaluate the safety of semaglutide injection (CA505) developed by Chongqing Chen'an Biopharmaceutical Co., Ltd. in the treatment of type 2 diabetes in adults, using the original drug semaglutide injection (Novota®) as a control. 2) To compare the similarity of key pharmacokinetic (PK) parameters (AUC0-τ, Css,min) between semaglutide injection (CA505) and Novota® in patients with type 2 diabetes after multiple doses.

Start Date04 Jul 2023

Sponsor / Collaborator

Shanghai BOWEI BIOMEDICAL CO., LTD

[+1]

CTR20222768 / CompletedPhase 1

司美格鲁肽注射液在健康受试者中的随机、开放、单次给药、两制剂、平行设计的药代动力学比对试验

[Translation] A randomized, open-label, single-dose, two-formulation, parallel-design pharmacokinetic comparison study of semaglutide injection in healthy subjects

评价受试制剂司美格鲁肽注射液（CA505注射液）与参比制剂司美格鲁肽注射液（诺和泰®）单次给药在健康成年受试者体内PK特征的相似性和安全性

[Translation]

To evaluate the similarity and safety of the PK characteristics of the test preparation semaglutide injection (CA505 injection) and the reference preparation semaglutide injection (Novotai®) in healthy adult subjects after a single dose

Start Date12 Nov 2022

Sponsor / Collaborator

Shanghai BOWEI BIOMEDICAL CO., LTD

[+1]

100 Clinical Results associated with Semaglutide biosimilar (Chongqing Chenan Biopharmaceutical &Shanghai Bovax Biotechnology)

100 Translational Medicine associated with Semaglutide biosimilar (Chongqing Chenan Biopharmaceutical &Shanghai Bovax Biotechnology)

100 Patents (Medical) associated with Semaglutide biosimilar (Chongqing Chenan Biopharmaceutical &Shanghai Bovax Biotechnology)

100 Deals associated with Semaglutide biosimilar (Chongqing Chenan Biopharmaceutical &Shanghai Bovax Biotechnology)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Phase 3	CN	Chongqing Chenan Biopharmaceutical Co., Ltd.	04 Jul 2023
Diabetes Mellitus, Type 2	Phase 3	CN	Shanghai BOWEI BIOMEDICAL CO., LTD	04 Jul 2023
Obesity	IND Approval	CN	Chongqing Chenan Biopharmaceutical Co., Ltd.	08 Jul 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis